KINIKSA ONE CONNECT

Serial Number 90567557
Registration 7811656
700

Registration Progress

Application Filed
Mar 9, 2021
Under Examination
Jan 4, 2022
Approved for Publication
Nov 9, 2021
Published for Opposition
Nov 9, 2021
Registered
May 27, 2025

Basic Information

Serial Number
90567557
Registration Number
7811656
Filing Date
March 9, 2021
Registration Date
May 27, 2025
Published for Opposition
November 9, 2021
Drawing Code
5

Status Summary

Current Status
Active
Status Code
700
Status Date
May 27, 2025
Registration
Registered
Classes
035 036 041 044

Rights Holder

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

83
Address
THIRD FLOOR, 23 OLD BOND STREET
LONDON W1S 4PZ
GB

Ownership History

Kiniksa Pharmaceuticals, Ltd.

Original Applicant
03
Hamilton HM 11 BM

Kiniksa Pharmaceuticals, Ltd.

Owner at Publication
03
Hamilton HM 11 BM

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

New Owner After Publication #1
83
LONDON GB

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

Original Registrant
83
LONDON GB

Legal Representation

Attorney
Maury M. Tepper, III

USPTO Deadlines

Next Renewal Deadline
2149 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-05-27)
Due Date
May 27, 2031
Grace Period Ends
November 27, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

48 events
Date Code Type Description
May 27, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 27, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER
May 7, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 7, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 29, 2025 ALIE A ASSIGNED TO LIE
Apr 29, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 29, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 15, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 11, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 28, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 28, 2025 GNRT O NON-FINAL ACTION E-MAILED
Mar 28, 2025 CNRT W SU - NON-FINAL ACTION - WRITTEN
Feb 28, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Feb 27, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 17, 2024 IUAF S USE AMENDMENT FILED
Dec 17, 2024 EISU I TEAS STATEMENT OF USE RECEIVED
Jul 3, 2024 EX5G S SOU EXTENSION 5 GRANTED
Jul 3, 2024 EXT5 S SOU EXTENSION 5 FILED
Jul 3, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 3, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Dec 30, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 28, 2023 EX4G S SOU EXTENSION 4 GRANTED
Dec 28, 2023 EXT4 S SOU EXTENSION 4 FILED
Dec 28, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 1, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 29, 2023 EX3G S SOU EXTENSION 3 GRANTED
Jun 29, 2023 EXT3 S SOU EXTENSION 3 FILED
Jun 29, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 4, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 2, 2023 EX2G S SOU EXTENSION 2 GRANTED
Jan 2, 2023 EXT2 S SOU EXTENSION 2 FILED
Jan 2, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 5, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 1, 2022 EX1G S SOU EXTENSION 1 GRANTED
Jul 1, 2022 EXT1 S SOU EXTENSION 1 FILED
Jul 1, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 4, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 9, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 9, 2021 PUBO A PUBLISHED FOR OPPOSITION
Oct 20, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 4, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 4, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED
Oct 4, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 4, 2021 GNEA F EXAMINERS AMENDMENT E-MAILED
Oct 4, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN
Oct 2, 2021 DOCK D ASSIGNED TO EXAMINER
Jun 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 12, 2021 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 035
Promoting awareness of patient support offerings for autoimmune and autoinflammatory diseases and disorders; business administration of reimbursement and healthcare benefit information for autoimmune and autoinflammatory diseases and disorders and their treatment
First Use Anywhere: 20210400
First Use in Commerce: 20210400
Class 036
insurance services, namely, benefits verification in the nature of insurance claims administration; providing online financial assistance with insurance benefits and coverage for health care providers and patients in the fields of autoimmune and autoinflammatory diseases and disorders
First Use Anywhere: 20210400
First Use in Commerce: 20210400
Class 041
Educational services, namely, conducting educational programs in the nature of webinars in the fields of autoimmune and autoinflammatory diseases and disorders and treatment and patient support options for these conditions
First Use Anywhere: 20210400
First Use in Commerce: 20210400
Class 044
Providing medical information for health care providers and patients in the fields of autoimmune and autoinflammatory diseases and disorders; medical support services, namely, providing healthcare information to patients and healthcare professionals in the fields of autoimmune and autoinflammatory diseases and disorders
First Use Anywhere: 20210400
First Use in Commerce: 20210400

Additional Information

Design Mark
The mark consists of the term "KINIKSA" above and left justified with the words "ONECONNECT" with the "E" in "ONE" linked to the "C" in "CONNECT"; the color gray represents shading and contrast only and is not a feature of the mark.
Translation
The wording "KINIKSA" has no meaning in a foreign language.

Classification

International Classes
035 036 041 044